Marengo Therapeutics Shares Promising Phase 2 Results for Breast Cancer Treatment at AACR 2026

Marengo Therapeutics Presents Groundbreaking Clinical Trial Results at AACR 2026

Marengo Therapeutics, Inc., a pioneering company in precision immunotherapy focusing on oncology and inflammation, has recently unveiled compelling results from its ongoing clinical studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting held in San Diego, California. This year's event, occurring from April 17 to 22, showcased critical advancements in the company’s therapeutic pipeline, particularly highlighting the clinical combination of invikafusp alfa and TRODELVY® for treating metastatic breast cancer.

In the late-breaking news, Marengo's preliminary Phase 2a clinical results from the STARt-002 trial were particularly striking. The study assessed the safety and efficacy of invikafusp alfa combined with TRODELVY® (sacituzumab govitecan-hziy), revealing confirmations of complete responses in patients suffering from heavily pretreated aggressive metastatic breast cancer subtypes, including triple-negative breast cancer (TNBC) and hormone receptor-positive (HR+)/HER2-negative variants. These findings are considered a significant leap forward in offering new hope to patients facing high-unmet medical needs in their treatment journeys.

Kevin Chin, M.D., the Chief Medical Officer at Marengo Therapeutics, expressed excitement over these promising results, emphasizing the scientific rationale behind combining invikafusp alfa with ADC (antibody-drug conjugate) therapy. “The notable observation of confirmed complete responses in heavily pretreated breast cancer patients reinforces our confidence in this innovative combination therapy,” said Dr. Chin. As patient enrollment for the trial progresses, the company anticipates releasing further data that will further validate their therapeutic platform and inform clinical practice, offering potential new treatment options in this challenging disease area.

The Phase 2a data builds on encouraging results previously discussed at the San Antonio Breast Cancer Symposium in 2025. The combination therapy has displayed a favorable safety profile consistent with the individual drugs involved, indicating a tolerable regimen for severely affected patients. In addition, pharmacodynamic studies have shown that invikafusp alfa effectively activates T cells while promoting robust expansion of specific T cell populations, a critical factor in mediating anti-tumor immunity.

In parallel, Marengo is advancing its STAR program through a significant collaboration with Ipsen. The focus is on a new T cell activator, IPN01203/STAR0501, which aims to selectively enhance T cells' ability to recognize and attack tumors. This promising candidate is also set to be presented at the AACR in a session titled “New Drugs on the Horizon,” marking its first public disclosure. David Jenkins, Senior Vice President at Ipsen, highlighted the importance of this mutual venture: “Our collaboration with Marengo is paving the way for groundbreaking precision T cell activation approaches that could alter the treatment landscape for solid tumors.”

The STAR program, encompassing Marengo's Selective T Cell Activation Repertoire (STAR), seeks to optimize therapy through its tailored fusion antibodies targeting T cell subsets related to diseases. By heading into early trials with two distinctive dual T cell agonists, Marengo is showcasing its commitment to advancing efficacious therapies that operate on innovative mechanisms of action, balancing both effectiveness and patient safety. While preliminary data show promise, Marengo remains committed to extensive clinical evaluations as they explore and refine these exciting treatment modalities.

As the global medical community pays attention, Marengo Therapeutics is set to release additional info on the trial outcomes and strategic developments. Their powerful combination of scientific insight, dedication, and spirited innovation holds the potential to create new avenues for treating patients battling cancer. The company’s vision aims to craft a landscape where personalized immunotherapy significantly improves survival rates against cancer and autoimmune diseases.

For further information, interested parties can keep an eye on Marengo Therapeutics' official communications and presentations during the ongoing AACR meeting, with details regarding their innovative research initiatives.

Note: Participants interested in joining the trials or learning more about Marengo's therapies are encouraged to visit the clinical trials registry for ongoing updates.